Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model.

Köhler M, Ehrenfeld S, Halbach S, Lauinger M, Burk U, Reischmann N, Cheng S, Spohr C, Uhl FM, Köhler N, Ringwald K, Braun S, Peters C, Zeiser R, Reinheckel T, Brummer T.

Oncogene. 2019 Feb;38(8):1324-1339. doi: 10.1038/s41388-018-0663-8. Epub 2019 Jan 18.

PMID:
30659267
2.

lncRNA LOC100132354 promotes angiogenesis through VEGFA/VEGFR2 signaling pathway in lung adenocarcinoma.

Wang Y, Zhang F, Wang J, Hu L, Jiang F, Chen J, Chen J, Wang L.

Cancer Manag Res. 2018 Oct 5;10:4257-4266. doi: 10.2147/CMAR.S177327. eCollection 2018.

3.

Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.

Roskoski R Jr.

Pharmacol Res. 2018 Sep;135:239-258. doi: 10.1016/j.phrs.2018.08.013. Epub 2018 Aug 15. Review.

PMID:
30118796
4.

DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, is a putative tumor suppressor.

Kanno E, Kawasaki O, Takahashi K, Takano K, Endo T.

Exp Cell Res. 2018 Jan 1;362(1):111-120. doi: 10.1016/j.yexcr.2017.11.008. Epub 2017 Nov 10.

PMID:
29129563
5.

Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.

Noeparast A, Teugels E, Giron P, Verschelden G, De Brakeleer S, Decoster L, De Grève J.

Oncotarget. 2016 Aug 26;8(36):60094-60108. doi: 10.18632/oncotarget.11635. eCollection 2017 Sep 1.

6.

Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.

Okimoto RA, Lin L, Olivas V, Chan E, Markegard E, Rymar A, Neel D, Chen X, Hemmati G, Bollag G, Bivona TG.

Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13456-13461. Epub 2016 Nov 9.

7.

A Raf kinase inhibitor demonstrates antiviral activities both in vitro and in vivo against different genotypes of virulent Newcastle disease virus.

Yin R, Liu X, Zhang P, Chen Y, Xie G, Ai L, Xue C, Qian J, Bi Y, Chen J, Sun Y, Stoeger T, Ding Z.

Antiviral Res. 2016 Sep;133:140-4. doi: 10.1016/j.antiviral.2016.08.003. Epub 2016 Aug 4.

PMID:
27498149
8.

Cyclophilin D counteracts P53-mediated growth arrest and promotes Ras tumorigenesis.

Bigi A, Beltrami E, Trinei M, Stendardo M, Pelicci PG, Giorgio M.

Oncogene. 2016 Sep 29;35(39):5132-43. doi: 10.1038/onc.2016.42. Epub 2016 Mar 14.

PMID:
26973251
9.

Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.

Chen SH, Zhang Y, Van Horn RD, Yin T, Buchanan S, Yadav V, Mochalkin I, Wong SS, Yue YG, Huber L, Conti I, Henry JR, Starling JJ, Plowman GD, Peng SB.

Cancer Discov. 2016 Mar;6(3):300-15. doi: 10.1158/2159-8290.CD-15-0896. Epub 2016 Jan 5.

10.

RKIP Inhibits Local Breast Cancer Invasion by Antagonizing the Transcriptional Activation of MMP13.

Datar I, Feng J, Qiu X, Lewandowski J, Yeung M, Ren G, Aras S, Al-Mulla F, Cui H, Trumbly R, Arudra SK, De Las Casas LE, de la Serna I, Bitar MS, Yeung KC.

PLoS One. 2015 Aug 26;10(8):e0134494. doi: 10.1371/journal.pone.0134494. eCollection 2015.

11.

DA-Raf-Mediated Suppression of the Ras--ERK Pathway Is Essential for TGF-β1-Induced Epithelial-Mesenchymal Transition in Alveolar Epithelial Type 2 Cells.

Watanabe-Takano H, Takano K, Hatano M, Tokuhisa T, Endo T.

PLoS One. 2015 May 21;10(5):e0127888. doi: 10.1371/journal.pone.0127888. eCollection 2015.

12.

SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.

Mazur PK, Reynoird N, Khatri P, Jansen PW, Wilkinson AW, Liu S, Barbash O, Van Aller GS, Huddleston M, Dhanak D, Tummino PJ, Kruger RG, Garcia BA, Butte AJ, Vermeulen M, Sage J, Gozani O.

Nature. 2014 Jun 12;510(7504):283-7. doi: 10.1038/nature13320. Epub 2014 May 21.

13.

DA-Raf-dependent inhibition of the Ras-ERK signaling pathway in type 2 alveolar epithelial cells controls alveolar formation.

Watanabe-Takano H, Takano K, Sakamoto A, Matsumoto K, Tokuhisa T, Endo T, Hatano M.

Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):E2291-300. doi: 10.1073/pnas.1321574111. Epub 2014 May 19.

14.

Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.

Imielinski M, Greulich H, Kaplan B, Araujo L, Amann J, Horn L, Schiller J, Villalona-Calero MA, Meyerson M, Carbone DP.

J Clin Invest. 2014 Apr;124(4):1582-6. doi: 10.1172/JCI72763. Epub 2014 Feb 24.

15.

Thrombin-induced NF-κB activation and IL-8/CXCL8 release is mediated by c-Src-dependent Shc, Raf-1, and ERK pathways in lung epithelial cells.

Lin CH, Yu MC, Chiang CC, Bien MY, Chien MH, Chen BC.

Cell Signal. 2013 May;25(5):1166-75. doi: 10.1016/j.cellsig.2013.01.018. Epub 2013 Jan 26.

PMID:
23357535
16.

Raf and PI3K are the molecular targets for the anti-metastatic effect of luteolin.

Kim HY, Jung SK, Byun S, Son JE, Oh MH, Lee J, Kang MJ, Heo YS, Lee KW, Lee HJ.

Phytother Res. 2013 Oct;27(10):1481-8. doi: 10.1002/ptr.4888. Epub 2012 Nov 21.

PMID:
23172826
18.

BAY61-3606 affects the viability of colon cancer cells in a genotype-directed manner.

Lau KS, Zhang T, Kendall KR, Lauffenburger D, Gray NS, Haigis KM.

PLoS One. 2012;7(7):e41343. doi: 10.1371/journal.pone.0041343. Epub 2012 Jul 18.

19.

Receptor tyrosine kinase inhibitors in rodent pulmonary hypertension.

Moreno-Vinasco L, Garcia JG.

Adv Exp Med Biol. 2010;661:419-34. doi: 10.1007/978-1-60761-500-2_27. Review.

20.

Involvement of Ras/Raf-1/p44/42 MAPK in YC-1-induced cyclooxygenase-2 expression in human pulmonary epithelial cells.

Chang MS, Chen BC, Weng CM, Lee WS, Lin CH.

Pharmacol Res. 2009 Oct;60(4):247-53. doi: 10.1016/j.phrs.2009.03.015. Epub 2009 Apr 2.

PMID:
19717011

Supplemental Content

Loading ...
Support Center